Public Health, Access to HIV AIDS Medicines and WTO: The Doha Declaration and its Aftermath

CONTENTS
TABLE OF CASES;
TABLE STATUTES;
CHAPTER I;
INTRODUCTION;
CHAPTER II;
RESEARCH METHODOLOGY;
2.1. Aims And Objectives;
2.2. Scope And Limitation;
2.3. Method or Analysis;
2.4. Sources of Data;
2.5 - Research Questions;
2.6. Mode or Citation;
CHAPTER III;
WTO AND THE NEW TRADE REGIME: THE TRIPS AGREEMENT;
3.1 - The Nature or Property As Intellectual Property;
3.2 - The Development of the Trips Agreement;
3.3 - Objectives and Principles of TRIPS;
3.4 - Pertinent Provisions of Trips And The Pharmaceutical Industry;
3.5 - The TRIPs Agreement and the Developing Nations;
CHAPTER IV;
THE PHARMACEUTICAL INDUSTRY AND DEVELOPING WORLD;
4.1 - The Global Pharmaceutical Situation;
4.2 - Pharmaceuticals In Developing Countries;
4.3 Medication The Pharmaceutical Industry And Access To Hiv / Aids medication;
CHAPTER V;
ACCESS TO HIV / AIDS DRUGS: A HUMAN RIGHTS PERSPECTIVE;
5.1 - Patent Protection For Pharmaceuticals And International Human Rights;
5.2 - Right To Health Care And Essential Medicines;
5.3 - HIV / AIDS Treatment Access & Human Rights;
5.4 - The Human Right Liability of Pharmaceutical Companies;
5.5 - HIV / AIDS Public Health Crisis as a National Emergency;
CHAPTER VI;
SOUTH AFRICA'S FIGHT FOR HIV / AIDS MEDICATION: AN ANALYSIS;
6.1 - History of HIV / AIDS Drug Availability in South Africa;
6.2 - The South African Response To Limited HIV / AIDS Drug Availability;
6.3 - Analysis of South Africa Medicines and Related Substances Control Amendment Act;
6.4 - Pharmaceutical Corporations v. South Africa: The Quest for Increased Drug Availability;
6.5 - The Final Outcome;
CHAPTER VII;
BATTLING THE AIDS CRISIS: THE EXPERIENCE OF OTHER DEVELOPING COUNTRIES;
7.1 – Brazil;
7.2 – Thailand;
CHAPTER VIII;
INDIA'S HISTORY AND CURRENT STATUS OF HIV/AIDS MEDICATION ;
8.1 - Patent Protection in India from 1970 to 2002;
8.2 - The Pharmaceutical Industry in India;
8.3 - The Indian Pharmaceutical Industry and the Doha Declaration
CHAPTER IX;
THE EVOLUTION OF THE DOHA DECLARATION TRIPS AND PUBLIC HEALTH ;
9.1 - The Content of the Declaration: The Role of Generic Medicines;
9.2 - The Role played by International Institutions;
9.3 - Role Played by Non - Governmental Organizations NGOs;
9.4. Role-played Organization of the Developing Country Group ;
9.5 - Meeting of the TRIPs Council - 20 June 2001;
9.6. Interim Preparations;
9.7. Intervention of Anthrax and Cipro;
9.8 - The Meeting on 27 October 2001;
CHAPTER X;
THE MANDATE OF THE DOHA DECLARATION OF TRIPS AND PUBLIC HEALTH;
10.1 - An Analysis of Doha Declaration;
10.2 - Drug Industry Response to the WTO Declaration on TRIPS and Public Health;
CHAPTER XI;
THE LEGAL ANALYSIS OF THE DOHA DECLARATION ON TRIPS AND PUBLIC HEALTH;
11.1 - The Doha Declaration of Evidence under Subsequent Practice TRIPS;
11.2 - The Doha Declaration as a Legally Non - Binding Statement of Intent and Commitment;
CHAPTER XII;
AFTERMAT TRIPS AND PUBLIC HEALTH ON DECLARATION: THE POST. DOHA AGENDA;
12.1 Issue an Official Interpretation on Public Health;
12.2 Designate WHO's Official Organization to Provide Technical Assistance on TRIPs - Related Health Issues;
12.3 Issue a Formal Interpretative Statement Clarifying TRIPS Article 30 Exceptions;
12.4 Safeguards Against Abuse Must Be Implemented;
12.5 Compile a Database of Generic Products;
12.6 - WTO Ministerial Meeting at Sydney;
12.7 TRIPS Council Meeting in November 2002;
CHAPTER XIII;
CONCLUSION;
BIBLIOGRAPHY;
Articles;
Books;
Agreements;
Constitutions;
Covenant;
Declaration;
Internet references;
Press releases;
Reports
Miscellaneous.